There have been hundreds of millions of cases of coronavirus disease 2019 (COVID-19),
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With …

Treatment with β-blockers is the main strategy for managing patients with heart failure and
reduced ejection fraction because of their ability to reverse the neurohumoral effects of the …

Maintenance of normal cardiac rhythm requires coordinated activity of ion channels and
transporters that allow well-ordered propagation of electrical impulses across the …

Ischemic cardiomyopathy (ICM) is a prominent form of heart failure, but the molecular
mechanisms underlying ICM remain relatively understudied due to marked phenotypic …

Background Within the last 5 years, cardiac society guidelines have begun to acknowledge
shared decision making (SDM) for the athlete with sudden cardiac death–predisposing …

β-blockers is a vast group of antiarrhythmic drugs which differ in their pharmacokinetic and
chemical properties. Some of them block β-adrenergic receptors selectively while the others …

Ventricular arrhythmias (Vas) are a life-threatening condition and preventable cause of
sudden cardiac death (SCD). With the increased utilization of implantable cardiac …

Landiolol is an ultra-short-acting, selective β1-adrenergic receptor blocker that was
originally approved in Japan for the treatment of intraoperative tachyarrhythmias. It has …

Beta-blockers are a class of medications that act on beta-adrenergic receptors and are
categorized as cardioselective and non-selective. They are principally used to treat …

Animal experimentation is key in the evaluation of cardiac efficacy and safety of novel
therapeutic compounds. However, interspecies differences in the mechanisms regulating …